GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » Gross Profit

NXL (Nexalin Technology) Gross Profit : $0.13 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology Gross Profit?

Nexalin Technology's gross profit for the three months ended in Dec. 2024 was $0.02 Mil. Nexalin Technology's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.13 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Nexalin Technology's gross profit for the three months ended in Dec. 2024 was $0.02 Mil. Nexalin Technology's Revenue for the three months ended in Dec. 2024 was $0.03 Mil. Therefore, Nexalin Technology's Gross Margin % for the quarter that ended in Dec. 2024 was 74.07%.

Nexalin Technology had a gross margin of 74.07% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 5 years, the highest Gross Margin % of Nexalin Technology was 88.07%. The lowest was 72.52%. And the median was 78.11%.


Nexalin Technology Gross Profit Historical Data

The historical data trend for Nexalin Technology's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology Gross Profit Chart

Nexalin Technology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
0.21 0.12 0.96 0.09 0.13

Nexalin Technology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.07 0.02 0.02 0.02

Competitive Comparison of Nexalin Technology's Gross Profit

For the Medical Devices subindustry, Nexalin Technology's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nexalin Technology's Gross Profit Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's Gross Profit distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's Gross Profit falls into.


;
;

Nexalin Technology Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Nexalin Technology's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.169 - 0.037
=0.13

Nexalin Technology's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0.027 - 0.007
=0.02

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Nexalin Technology's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.02 / 0.027
=74.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Nexalin Technology  (NAS:NXL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Nexalin Technology had a gross margin of 74.07% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Nexalin Technology Gross Profit Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Nexalin Technology Business Description

Traded in Other Exchanges
N/A
Address
1776 Yorktown, Suite 550, Houston, TX, USA, 77056
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Executives
David Owens director, officer: Chief Medical Officer 4545 HARRIS TRAIL NW, ATLANTA GA 30327
Marilyn Elson 10 percent owner, officer: Ms. Elson serves as CFO 32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad director 6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White director, officer: President/CEO 1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
Alan Kazden director 3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser other: Spouse
Ben Hu director 7021 EDGERTON ROAD, NORTH ROYALTON OH 44133

Nexalin Technology Headlines

From GuruFocus